Keyphrases
Tumor
100%
Regional Cerebral Blood Flow (rCBF)
100%
Erlotinib
100%
High-grade Glioma
100%
Supratentorial
100%
Post-radiotherapy
100%
Early Treatment Failure
100%
Dynamic Susceptibility Contrast Magnetic Resonance Imaging
100%
Cerebral Blood Volume
75%
Working Diagnosis
50%
Clinical Trials
50%
Perfusion
50%
Treatment Failure
50%
Pediatric Glioma
50%
Flow Ratio
50%
Treatment Response
25%
Patient Outcomes
25%
Magnetic Resonance Imaging
25%
Tumor Treatment
25%
Patient Treatment
25%
Perfusion Imaging
25%
Fluid-attenuated Inversion Recovery (FLAIR)
25%
T2-weighted Imaging (T2WI)
25%
T1-weighted Image
25%
Survival Time
25%
Tumor Outcome
25%
Cerebral Blood Flow
25%
Tumor Perfusion
25%
Time Since Death
25%
Patient Tumor
25%
Concurrent Radiotherapy
25%
Perfusion Parameters
25%
MRI Sequences
25%
Perfusion MRI
25%
Perfusion-weighted Image
25%
Sequential Radiotherapy
25%
Medicine and Dentistry
Magnetic Resonance Imaging
100%
Ganglioglioma
100%
Brain Blood Flow
100%
Erlotinib
100%
Dynamic Susceptibility Contrast
100%
Tumor
80%
Clinical Trial
40%
Pediatrics
40%
Treatment Response
20%
Neoplasm
20%
Cancer Treatment
20%
Scintigraphy
20%
Biopsy Technique
20%
Survival Time
20%
Perfusion Weighted Imaging
20%
Radiation Therapy
20%
Differential Scanning Calorimetry
20%
Neuroscience
Magnetic Resonance Imaging
100%
Magnetic Resonance Imaging
100%
Dynamic Susceptibility Contrast
100%
Erlotinib
100%
Radiation Therapy
50%